Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones.Wogelius P, Norgaard M, Gislum M, Pedersen L, Schonheyder HC, Sorensen HT.

Department of Clinical Epidemiology, Aarhus University Hospital, Aalborg, Denmark. aas.uxpiwo@nja.dk

In a database cohort study, the risk of adverse birth outcome in Danish women who redeemed a fluoroquinolone prescription during pregnancy was examined. Among 87 women who redeemed a fluoroquinolone prescription at any time during the pregnancy, the prevalence ratio of preterm birth was 1.4 (95% confidence interval (CI), 0.6-3.2), one woman had a stillbirth, and no children died during the perinatal period. Among 130 women who redeemed a prescription during the first trimester or 30 days before conception, the prevalence ratio of congenital malformation was 0.7 (95% CI, 0.3-2.0) and the prevalence ratio of bone malformations was 2.2 (95% CI, 0.7-6.7). Our study raises the concern that prenatal fluoroquinolone exposure may be associated with an increased risk of bone malformations.

PMID: 16144758 [PubMed - indexed for MEDLINE]